Inovio Q2 net loss narrows on warrant gain, lower costs

Inovio Pharmaceuticals

12/08/2026 21:14

Overview
US biotech firm's Q2 net loss narrowed yr/yr, driven by non-cash warrant gain
Q2 operating expenses fell due to lower compensation and development costs
Company had no revenue in Q2; cash runway into late Q1 2027 includes July offering proceeds

Outlook
Company expects FDA decision on INO-3107 by Oct. 30, 2026, with commercial preparations underway
Inovio estimates cash, equivalents and investments will fund operations into late Q1 2027
Company continues discussions with potential partners to accelerate next-generation DNA medicine programs

Result Drivers
LOWER R&D AND ADMIN COSTS - Co said Q2 operating expenses fell due to lower employee and consultant compensation, reduced engineering services, and lower inventory expenses
NON-CASH WARRANT GAIN - Net loss narrowed mainly due to a $13.9 mln non-cash gain on fair value adjustment of warrant liabilities

Company press release: ID:nPn1LYyxja

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.07
 
Q2 Net Loss
 
$6.01 mln
 
Q2 Operating Expenses
 
$18.62 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $2.50, about 226.5% above its August 11 closing price of $0.77

Reuters Recommended Reads
Aug 12 - Unicycive Therapeutics Q2 net loss narrows on warrant liability change
Aug 11 - Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Aug 11 - Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)